On 16 Oct 2008 at 11:19, Hembling, Ian wrote:
> This is aimed at those of you in the UK especially those who are
> Clinical Scientists or Biomedical Scientists.
>
> Most of the listening events are complete now.
> I was just interested in anyone's views on Professor Sue Hill's latest
> venture and the impact on how we do business.
Ian:
You'll need to be more specific to get any useful input!
- professional societies have been engaged in the MSC process for a
year or more already
- the model has evolved demonstrably towards that shown at the
current series of events, which may not be the final version to be
published by DH in November and launched at the CSO Conference
(25-26/11/08)
- it's unclear whether you are supportive or not, and what you mean
by "how we do business"
Finally, it would be helpful if your signature file included your post/role
- your email address merely gives your name and the Trust which has
provided you with an email address
David
Dr David Bullock
Director, UK NEQAS
Birmingham Quality
P O Box 3909
Birmingham B15 2UE
FAX 0121 414 1179 [+44 121 414 1179]
------ACB discussion List Information--------
This is an open discussion list for the academic and clinical
community working in clinical biochemistry.
Please note, archived messages are public and can be viewed
via the internet. Views expressed are those of the individual and
they are responsible for all message content.
ACB Web Site
http://www.acb.org.uk
List Archives
http://www.jiscmail.ac.uk/lists/ACB-CLIN-CHEM-GEN.html
List Instructions (How to leave etc.)
http://www.jiscmail.ac.uk/
|